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We studied whether ﬁve sessions of 10Hz repetitive transcranial magnetic stimulation (rTMS treatment) applied over the dorso-
lateral prefrontal cortex (DLPFC) or the primary motor cortex (MC) in advanced Parkinson’s disease (PD) patients would have
any eﬀect on L-dopa-induced dyskinesias and cortical excitability. We aimed at a randomised, controlled study. Single-pulse tran-
scranial magnetic stimulation (TMS), paired-pulse transcranial magnetic stimulation, and the Uniﬁed Parkinson’s Disease Rating
Scale (UPDRS parts III and IV) were performed prior to, immediately after, and one week after an appropriate rTMS treatment.
Stimulation of the left DLPFC induced a signiﬁcant motor cortex depression and a trend towards the improvement of L-dopa-
induced dyskinesias.
Copyright © 2008 I. Rektorova et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
TheneuralmechanismsthatunderlieL-dopa-induceddyski-
nesias in Parkinson’s disease (PD) remain poorly understood
[1–4]. Dyskinesias have been associated with pulsatile stimu-
lation of dopamine receptors, downstream changes in genes
and proteins, and changes in nondopamine transmitter sys-
tems [4–6]. All these changes lead to alterations in the ﬁring
patterns within the basal ganglia, causing overactivations of
the primary motor cortex and premotor cortical areas [7, 8].
Activation studies in PD patients (H2
15O positron emission
tomography (PET) and 133Xe single photon emission com-
puted tomography (SPECT)) are in line with these results,
and indicate that L-dopa-induced dyskinesias are associated
with inappropriate overactivity of striatofrontal projections
both at rest and during volitional actions [2, 9]. Compari-
son of rest with dyskinesias versus rest without dyskinesias
showed a relative activation of the motor cortex, the lateral
and mesial premotor areas including the supplementary mo-
tor area (SMA), the dorsal prefrontal cortex, and the basal
ganglia. The comparison of dyskinetic versus nondyskinetic
states during voluntary movement revealed additional acti-
vation of the same brain regions [9]. Unfortunately, in the
PET study of Brooks et al. [9] mentioned above, regional
cerebral blood ﬂow (rCBF) in PD patients with and with-
out L-dopa induced dyskinesias was not compared to that
of healthy subjects, and therefore, it is diﬃcult to speculate
whether the relative increases in rCBF observed in patients
with dyskinesias were in fact above or still below that of con-
trols in all the reported areas including the DLPFC.
Repetitive transcranial magnetic stimulation (rTMS) can
producechangesinexcitabilityofcorticalcircuitsthatoutlast
theperiodofstimulation,openingthepossibilityofinterven-
ing directly with the mechanisms of cortical plasticity in the
humancortex.rTMSisalsoasuitabletooltoinvestigateplas-
ticity within a distributed functional network since condi-
tioning eﬀects of rTMS are not limited to the stimulated area
but give rise to functional changes in interconnected corti-
cal areas. The magnitude and the direction of rTMS-induced
plasticity depend on extrinsic factors (i.e., the variables of
stimulation such as intensity, frequency, and total number of
stimuli) and intrinsic factors (i.e., the functional state of the
cortex targeted by rTMS). High frequencies of rTMS applied
over the motor cortex lead to facilitatory aftereﬀects on cor-
ticospinal excitability while low-frequency stimulations lead
to opposite (i.e., inhibitory) aftereﬀects (for review, see 10).2 International Journal of Biomedical Imaging
The main problem remains, that the basic mechanisms me-
diating the eﬀects of rTMS are still poorly understood.
Recenly,severalstudieshavesuggestedthetherapeuticef-
ﬁcacy of rTMS in PD while other studies have found no clin-
ical improvement of motor performance in PD [11–15]. Us-
ing rTMS over the SMA, an Italian group [4] showed that
900 pulses of 1Hz rTMS with an intensity set at 90% of the
resting motor excitability threshold markedly reduced drug-
induced dyskinesias in 8 advanced PD patients. In spite of
this promising result, a year later the same group [16] dis-
covered that 5 repeated sessions of the 1Hz rTMS failed to
enhance and/or prolong the beneﬁcial eﬀects of the proce-
dure, and thus could not be considered clinically useful. Very
similar results were reported by a Toronto group [17]w h o
used the same stimulation parameters but targeted the pri-
mary motor cortex contralateral to the side with more severe
dyskinesias in 6 PD patients. Although the beneﬁt was evi-
dent at day 1 after a two-week course of rTMS, the authors
havenotmanagedtoobtainmoresustainedclinicalimprove-
ment after the treatment.
We recently reported the results of a pilot study that
investigated whether 5 repeated sessions of high frequency
rTMS at 10Hz applied over the motor cortex (MC) of the
relevant leg or over the left dorsolateral prefrontal cortex
(DLPFC) might result in a modiﬁcation of “oﬀ”-related
freezing of gait and motor symptoms of PD in 6 advanced
PDpatients[18].TheselectionofMCandDLPFCtargetsfor
rTMS was based on dopamine release in the putamen and
caudate, respectively [19, 20]. The target selection was fur-
ther supported by the results of Lomarev et al. [14] who had
reportedpositivecumulativebeneﬁtofhigh-frequencyrTMS
appliedoverthesametargetsforimprovinggait,aswellasre-
ducing upper limb bradykinesia in PD patients. In our study,
rTMS was well tolerated. Despite a reported trend towards
improvement of the Stroop test interference after rTMS over
the left DLPFC, freezing of gait and motor symptoms of PD
remained unchanged by rTMS.
Interestingly, patients who had undergone the DLPFC
treatment reported a subjective improvement of their dyski-
nesias.Therefore,inthispaper,wepresentaposthocanalysis
of the data from the same group of patients that focuses on
cortical excitability and on the possible modiﬁcation of L-
dopa-induced dyskinesias by repeated sessions of rTMS over
the DLPFC.
2. PATIENTS AND METHODS
We studied 6 patients (5 men and 1 woman, mean age
67.3 ± 7.7 years) with advanced PD according to the UK
Parkinson’s Disease brain bank criteria [21, 22], a Hoehn-
Yahr stage [23] between 2.5 and 4 while in the “oﬀ” state,
and without dementia (Mini-Mental State Examination [24]
score > 24). A Montgomery-Asberg Depression Rating Scale
[25] cut-oﬀ score of 14 was used to exclude patients with de-
pression. Patients with a predominant tremor form of PD
were also excluded from the study. All patients had dyski-
nesias, motor ﬂuctuations, and “oﬀ”-related freezing of gait.
The disease duration was 11.3 ± 3.1 years. The daily L-dopa
dose equivalent was 1145.8 ± 413.2mg; all patients were on
L-dopa ± entacapone plus a dopamine receptor agonist. The
antiparkinsonian medication was stable for at least 4 weeks
prior to the study commencement and during the study. All
patients signed the informed consent form, which was ap-
proved by the Ethics Committee of Saint Anne’s Hospital in
Brno.
rTMS was applied over the left DLPFC (5cm anterior to
theoptimumscalppositionforactivationofthecontralateral
ﬁrst dorsal interosseus muscle [26]) or over the optimal po-
sition for the tibialis anterior muscle contralateral to the foot
which was most frequently used by the patient to make the
ﬁrst step after freezing of gait (i.e., MC), using the Magstim
Super Rapid stimulator and a ﬁgure-of-eight coil with a
mean diameter of 7cm. The coil was placed tangentially to
the scalp with the handle pointing backwards and laterally
at 45
◦ angle away from the midline inducing a posterior-
anteriorcurrentinthebrain.Nowadays,theframelessstereo-
taxy has been used in order to target the region of brain
corresponding to cytoarchitectonic area 9/46 as deﬁned by
Petrides and Pandya [27]. Nevertheless, this part of the brain
wasfoundtooverlapwiththeregiontargetedbythestandard
procedure (Rektorova and Paus, unpublished data), used in
most studies.
rTMS was delivered in the “on” state (i.e., when PD med-
ication was working and providing beneﬁt) without dyskine-
sias according to the individual patients’ diaries, at the same
timeofday.Onetreatmentconsistedof5sessionsover5con-
secutive days. We chose a repeated sessions design, and our
patients were stimulated while being in their “on” state since
both conditions have been associated with better rTMS out-
c o m e si nl i t e r a t u r e[ 12, 14]. One session consisted of 1350
pulses delivered at 10Hz frequency, at an intensity of 90%
of the resting motor excitability threshold (for the right ﬁrst
dorsal interosseus muscle when stimulating the left DLPFC,
andtheappropriatetibialisanteriormusclewhenstimulating
the MC). Each patient completed at least one rTMS treat-
ment. The order of stimulation sites was randomized using
closed envelopes. Although we aimed at a crossover design,
only two patients completed both treatments (with a one-
month interval between them).
In order to ensure the method was safe with regard to
cognitive functions, a brief neuropsychological battery of
tests was administered prior to, immediately after, and one
week after each rTMS treatment. The results have been pub-
lished elsewhere [18].
Experiencedneurologists whowereblinded tothestimu-
lation site performed a neurological evaluation prior to, im-
mediately after, and one week after appropriate rTMS treat-
ment.Theevaluationwasconductedduringthepatients’rel-
ative “oﬀ” state (i.e., when PD medication was not improv-
ing PD symptoms resulting in a lack of mobility) accord-
ing to the individual patients’ diaries, at the same time of
day. It consisted of the UPDRS, part III (motor examination)
and part IV (treatment complications) [28]. A more detailed
evaluation and analysis of gait and “oﬀ”-related freezing of
gait has been reported elsewhere [18].
Single-pulse and paired-pulse TMS was performed while
the patient was “on” to study the eﬀects of rTMS treat-
ments on cortical excitability. We used the paired-pulse TMSI. Rektorova et al. 3
Table 1: Eﬀects of rTMS treatments on motor symptoms of PD and treatment complications as assessed by the UPDRSs III and IV. UPDRS
III: Uniﬁed Parkinson’s Disease Rating Scale, part III, motor examination; UPDRS IV: Uniﬁed Parkinson’s Disease Rating Scale, part IV,
treatment complications; Pre-rTMS/MC: prior to the repetitive transcranial magnetic stimulation treatment applied over the motor cortex;
Post-rTMS/MC:immediatelyaftertherepetitivetranscranialmagneticstimulationtreatmentappliedoverthemotorcortex;Pre-rTMS/PFC:
prior to the repetitive transcranial magnetic stimulation treatment applied over the prefrontal cortex; Post-rTMS/PFC: immediately after the
repetitive transcranial magnetic stimulation treatment applied over the prefrontal cortex.
Pre-rTMS/MC scores Post-rTMS/MC scores Pre-rTMS/PFC scores Post-rTMS/PFC scores
UPDRS III “on” 21.25 ±13.43 21.75 ±13.67 20.75 ±12.87 20.00 ±14.12
UPDRS IV 6.00 ±1.83 7.00 ±2.50 6.25 ±1.71 4.75 ±0.96
paradigm of Ridding et al. [29] at interstimulus intervals
(ISI) of 1, 3, 7, and 15 milliseconds [30]. We evaluated motor
evoked potentials (MEPs) elicited by single and paired-pulse
TMS pulses over the MC contralateral to either the right ﬁrst
dorsal interosseus muscle (prior to, immediately after, and
one week after the rTMS treatment over the left DLPFC)
or the appropriate tibialis anterior muscle (prior to, imme-
diately after, and one week after the rTMS treatment over
the appropriate MC). The motor cortical sites were chosen
to speciﬁcally accommodate the primary goal of our freez-
ing of gait protocol design. A circular coil was used. MEP
sizereﬂectsmoregloballythecorticospinalinput-outputbal-
ance, excitatory inputs from high-threshold glutamatergic
pathways to the motor cortex lead to intracortical facilita-
tion, whereas inhibitory inputs from low-threshold GABA-
A-mediated pathways lead to intracortical inhibition at short
ISI [13].
3. STATISTICAL ANALYSIS
The eﬀects of rTMS treatments on single MEP amplitudes
and UPDRS before and after the rTMS treatments were anal-
ysed by a two-tailed paired-sample t test. A two-factor re-
peated measures ANOVA, with the factors of “TIME” (3 lev-
els: baseline, immediately after the rTMS treatment, and 1
week after the rTMS treatment) and “ISI” (3 levels: averaged
data from the inhibiting ISI (1 and 3 milliseconds), the facil-
itating ISI (15 milliseconds), and the intermediate ISI (7 mil-
liseconds))wasperformedtoevaluatetheeﬀectsoftherTMS
treatment applied over the MC and the DLPFC, respectively.
4. RESULTS
4.1. Clinicaleffects
Despite our aim to perform a randomised crossover design,
the study was stopped prematurely as several patients with-
drew the consent form before completing both treatments. A
subjective lack of treatment eﬀect on freezing of gait (i.e., the
primary outcome) was the reason for the study withdrawal.
This study presents the results from four patients that com-
pleted the rTMS treatment over the MC and four patients
that completed the treatment over the DLPFC. Despite the
lack of eﬀect of rTMS on freezing of gait and motor symp-
toms of PD [18], the patients reported a decreased frequency
and intensity of dyskinesias after 5 consecutive sessions of
rTMS targeted over the left DLPFC. These changes were re-
ﬂected by the mean UPDRS IV decrease immediately after
5 sessions of the stimulation as compared with the baseline
scores (see Table 1). The result did not reach statistical sig-
niﬁcance (P = .06) but could be suggestive of a mild im-
provement of dyskinesias. No such changes were observed
after rTMS of the MC.
4.2. Effectsoncorticalexcitability
There was no cumulative eﬀect of the rTMS treatment over
the MC on corticospinal excitability as measured by MEP
responses produced by single TMS pulses over the left MC
contralateral to the appropriate tibialis anterior muscle (see
Table 2). However, we found that 5 consecutive sessions of
high frequency rTMS of the left DLPFC produced a signiﬁ-
cant decrease in the amplitude of MEP responses produced
by single TMS pulses over the left MC contralateral to the
right ﬁrst dorsal interosseus muscle (see Table 2).
TherewerenoeﬀectsofanyrTMStreatmentsonthetime
course of intracortical inhibition or intracortical facilitation
in the appropriate motor cortex; this was veriﬁed with a two-
factor repeated measures ANOVA with the factors “TIME”
and “ISI”: F(4,26) = 0.72, P = .6 for rTMS treatment over
the DLPFC; F(4,10) = 2.4, P = .1 for rTMS treatment over
the MC.
5. DISCUSSION
The results of our study point to a possible impact of re-
peated sessions of rTMS applied over the left DLPFC on
L-dopa-induced dyskinesias in advanced PD patients. The
mean change in the UPDRS IV scores did not reach a sta-
tistical signiﬁcance, but we did not evaluate dyskinesias by
more appropriate standardized scales since the assessment of
dyskinesias was not the primary outcome of our pilot study.
On the other hand, UPDRS IV was used to test dyskinesias in
aPETstudybyBrooksetal.[9].Thereareanumberofhypo-
thetical mechanisms that might underlie the possible eﬀects
ofrTMSoftheDLPFConL-dopa-induceddyskinesiasinad-
vanced PD.
It appears that changes of the excitability of the primary
motor cortex may be more eﬃciently performed through
stimulation of premotor and/or other more anterior brain
regions,forreview,see[31].Wefoundthat5consecutiveses-
sions of high frequency rTMS of the left DLPFC produced a
signiﬁcant decrease in the amplitude of MEP responses pro-
ducedbysingleTMSpulsesovertheleftMCfortherightﬁrst
dorsal interosseus muscle (i.e., decrease of the cortico-spinal
excitability). These results are in accord with the results of4 International Journal of Biomedical Imaging
Table 2: Eﬀects of rTMS treatments on the amplitude of MEP responses produced by single TMS pulses. MEP: motor evoked potential; Pre-
rTMS/MC: prior to the repetitive transcranial magnetic stimulation treatment applied over the motor cortex; Post-rTMS/MC: immediately
after the repetitive transcranial magnetic stimulation treatment applied over the motor cortex; Pre-rTMS/PFC: prior to the repetitive tran-
scranial magnetic stimulation treatment applied over the prefrontal cortex; Post-rTMS/PFC: immediately after the repetitive transcranial
magnetic stimulation treatment applied over the prefrontal cortex.
Pre-rTMS/MC Post-rTMS/MC Pre-rTMS/PFC Post-rTMS/PFC
MEP amplitude µV) 1.60 ±0.79 1.52 ±0.68 2.02 ±0.10
∗ 1.22 ±0.32
∗
∗P = .03 (paired samples t test).
Rollnick et al. [32] who also demonstrated that stimula-
tion of the DLPFC via subthreshold 5Hz rTMS induces mo-
tor cortex depression in healthy subjects. It was posited by
the authors that this ﬁnding might be explained by the fact
that prefrontal brain areas contribute to motor cortex inhibi-
tion through antagonisms between frontal and parietal lobes
[32, 33] but the exact mechanisms are not fully understood.
Primary motor cortex “overactivity” in rather advanced PD
patientswasfoundbymeansofPETandfunctionalmagnetic
resonance imaging (fMRI) while studying simple or complex
motor hand tasks [34, 35]. It was also observed in SPECT
and PET studies of PD patients with L-dopa-induced dysk-
inesias [2, 9]. Electrophysiological data furhter support this
notion:increasedMEPaplitudesatrestwerefoundinPDpa-
tients with L-dopa induced dyskinesias [36, 37]. Neuroimag-
ing studies have shown that subthalamic nucleus stimulation
acts through the reduction of abnormal overactivity in the
m o t o rs y s t e ma tr e s t[ 34, 38]. Even though dyskinesias were
notsystematicallymonitoredinthesestudies,ithasbeenwell
known that subthalamic nucleus stimulation surgery is able
to reduce L-dopa-induced dyskinesias [39]. Taken together,
normalizing (i.e., reducing) the excitability of the primary
motor cortex, for example, by rTMS of the DLPFC might be
onepossiblefactorinimprovingL-dopa-induceddyskinesias
in advanced PD patients.
rTMS applied over the left DLPFC can induce signiﬁ-
cant increases of rCBF in the stimulated area [40]. Func-
tional imaging studies (PET and fMRI) report decreases in
rCBF and MRI signal in the DLPFC and the rostral SMA
in advanced PD patients compared to controls [35, 41–45].
The DLPFC is connected with the rostral SMA [46]. Palli-
dotomy [44] and subthalamic nucleus stimulation [47]r e -
versed such a hypoactivation. After unilateral pallidotomy,
glucose metabolism increased in the DLPFC, in addition
to metabolic changes in other cortical and subcortical ar-
eas [48]. rCBF increases were reported in the DLPFC and
the rostral SMA during apomorphine pumps [49]. Again,
pallidotomy, subthalamic nucleus stimulation and continu-
ous apomorphine are able to reverse dyskinesias [39, 49–51].
Therefore, the direct involvement of the DLPFC and the de-
generation of mesofrontal dopaminergic aﬀerents might also
be hypothesized to play some role in the development of
dyskinesias.
Finally, involvement of the dorsolateral “prefrontal” cir-
cuitmay wellbepossible. Theprefrontalcircuit encompasses
the dorsal prefrontal cortex, the dorsal caudate nucleus, the
dorsal medial globus pallidus, and the ventral anterior nu-
cleus of the thalamus. Strafella et al. have shown that high
frequency rTMS of the DLPFC leads to dopamine release in
the ipsilateral caudate nucleus [19, 20]. We used the same
parameters as Strafella et al. with regard to frequency and
intensity of stimulation. Therefore, subcortical mechanisms
cannot be excluded either.
Taken together, we have shown for the ﬁrst time that re-
peated sessions of subthreshold 10Hz rTMS of the DLPFC
induced signiﬁcant reductions of the ipsilateral motor cortex
excitability in advanced PD population, and might possibly
be suggestive of an improvement of L-dopa-induced dyski-
nesias. It has to be pointed out that this was a small obser-
vational study not speciﬁcally designed to assess dyskinesias
in PD. DLPFC stimulation was not controlled by the placebo
rTMS and therefore a possible placebo eﬀect cannot be ex-
cluded either [15]. On the other hand, the DLPFC stimu-
lation was controlled by yet another active stimulation over
the MC. Improvement of dyskinesia could not have been ex-
pected by patients since changes in the motor complications
score were not included in the primary outcomes of our pilot
study.
Further research is warranted to explore more precisely
whether the unilateral or bilateral stimulation of the DLPFC
via repeated sessions of high frequency rTMS induces bene-
ﬁcial eﬀects on L-dopa-induced dyskinesias in advanced PD
patients, and whether it could be considered clinically useful.
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